Your browser doesn't support javascript.
loading
Structure activity relationship studies on Amb639752: toward the identification of a common pharmacophoric structure for DGKα inhibitors.
Velnati, Suresh; Massarotti, Alberto; Antona, Annamaria; Talmon, Maria; Fresu, Luigia Grazia; Galetto, Alessandra Silvia; Capello, Daniela; Bertoni, Alessandra; Mercalli, Valentina; Graziani, Andrea; Tron, Gian Cesare; Baldanzi, Gianluca.
Afiliação
  • Velnati S; Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Massarotti A; Institute for Research and Cure of Autoimmune Diseases, CAAD, University of Piemonte Orientale, Novara, Italy.
  • Antona A; Department of Pharmaceutical Sciences, University of Piemonte Orientale, Novara, Italy.
  • Talmon M; Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Fresu LG; Department of Health Sciences, School of Medicine, University of Piemonte Orientale, Novara, Italy.
  • Galetto AS; Department of Health Sciences, School of Medicine, University of Piemonte Orientale, Novara, Italy.
  • Capello D; Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Bertoni A; Palliative Care Division, A.S.L., Vercelli, Italy.
  • Mercalli V; Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Graziani A; Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Tron GC; Department of Pharmaceutical Sciences, University of Piemonte Orientale, Novara, Italy.
  • Baldanzi G; Università Vita-Salute San Raffaele, Milan, Italy.
J Enzyme Inhib Med Chem ; 35(1): 96-108, 2020 Dec.
Article em En | MEDLINE | ID: mdl-31690133
A series of analogues of Amb639752, a novel diacylglycerol kinase (DGK) inhibitor recently discovered by us via virtual screening, have been tested. The compounds were evaluated as DGK inhibitors on α, θ, and ζ isoforms, and as antagonists on serotonin receptors. From these assays emerged two novel compounds, namely 11 and 20, which with an IC50 respectively of 1.6 and 1.8 µM are the most potent inhibitors of DGKα discovered to date. Both compounds demonstrated the ability to restore apoptosis in a cellular model of X-linked lymphoproliferative disease as well as the capacity to reduce the migration of cancer cells, suggesting their potential utility in preventing metastasis. Finally, relying on experimental biological data, molecular modelling studies allow us to set a three-point pharmacophore model for DGK inhibitors.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperazinas / Inibidores de Proteínas Quinases / Indóis / Lipase Lipoproteica Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperazinas / Inibidores de Proteínas Quinases / Indóis / Lipase Lipoproteica Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article